Polgreen, L. E. Et Al. 2023. Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: update from Phase 3 extension study. HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 3 , 149-151.

Polgreen, L. E., Savarirayan, R., Tofts, L., Irving, M., Wilcox, W. W., Bacino, C. A., ... Hoover-Fong, J.(2023). Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: update from Phase 3 extension study. HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 3, 149-151.

Polgreen, Lynda Et Al. "Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: update from Phase 3 extension study," HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 3, 149-151, 2023

Polgreen, Lynda E. Et Al. "Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: update from Phase 3 extension study." HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 3, pp.149-151, 2023

Polgreen, L. E. Et Al. (2023) . "Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: update from Phase 3 extension study." HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 3, pp.149-151.

@article{article, author={Lynda E. Polgreen Et Al. }, title={Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: update from Phase 3 extension study}, journal={HORMONE RESEARCH IN PAEDIATRICS}, year=2023, pages={149-151} }